Teng, N., Malfettone, A., Dalby, M., Kiu, R., Seki, D., Robinson, T., . . . Cortés, J. (2024). Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin.
Citación estilo ChicagoTeng, NM, et al. Profiling the Gut and Oral Microbiota of Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer Patients Receiving Pembrolizumab and Eribulin. 2024.
Cita MLATeng, NM, et al. Profiling the Gut and Oral Microbiota of Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer Patients Receiving Pembrolizumab and Eribulin. 2024.
Precaución: Estas citas no son 100% exactas.